News Boehringer eyes third quarter FDA verdict for oral HER2 drug Boehringer Ingelheim's oral HER2 inhibitor zongertinib has started an FDA review as a lung cancer treatment with a decision due in the third quarter.
News WCLC: Bayer, Boehringer face off on HER2 cancers Bayer and Boehringer Ingelheim both had new data on their HER2-targeting small-molecule drugs to present at the World Conference on Lung Cancer (WCLC), hoping to add new oral therapies to t